US FDA panel rejects Acura/King's abuse-deterrent analgesic
This article was originally published in Scrip
A US FDA advisory panel overwhelmingly recommended against approval of Acura Pharmaceuticals/King Pharmaceuticals' Acurox (oxycodone plus niacin) for the treatment of moderate to severe pain, citing inadequate evidence that inclusion of niacin in the combination product would deter misuse or abuse of the opioid oxycodone.
You may also be interested in...
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.
Use of expedited pathway based on drug’s effect on brain amyloid would be problematic given advisory committee’s views of a disconnect between biomarker data and clinical efficacy results; however, one FDA expert sees potential for agency to grant accelerated approval on basis of an intermediate clinical endpoint – the same endpoint on which Biogen seeks regular approval.